Skip to content
Resistance to change: How to facilitate the implementation of new methods in the lab
9th ECAT International Symposium 2014
Speaker
Titel
Abstract
Presentation
M. van leeuwen
Resistance to change: How to facilitate the implementation of new methods in the lab
Abstract not available!
Related items
Analytical Information :
19
Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban
A computer-based model to access costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assay
Pre-Analytical Issues in Platelet Function Testing - An Update
Minimum citrate tube fill volume for routine coagulation testing
Pre-Analytical Issues in Platelet Function Testing - An Update
Lupus anticoagulant testing: analyzing fresh samples after a single centrifugation and after a 6-8 hr delay
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
Update on platelet aggregation testing
The responsiveness of different APTT reagents to mild factor VIII, IX and XI deficiencies
Results of a workshop on the inter-laboratory variability of analysis of type 1 factor VIII Inhibitors
The use of quality indicators for the pre-analytical phase
Risk management for laboratory testing
Critical pre-examination variables in hemostasis testing
Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine
The do’s and don’ts of laboratory detection of haemostasis-inhibitors: lessons from a workshop
Comparison of two statistical software programs for determining reference intervals of screening coagulation assays
Assuring quality in the postanalytical phase
Analytical performance specifications for hemostasis parameters
The effect of Rivaroxaban on haemostasis assays; results from ECAT surveys
Cases :
28
How to monitor Haemophilia A patients switching from one therapy to another
Prekallikrein deficiency
Effect of high haematocrit levels on coagulation testing
Acquired von Willebrand disease and marginal zone lymphoma
Acquired protein S deficiency with purpura fulminans presentation in the aftermath of varicella zoster in a child
Two cases of autosomal dominant macrothrombocytopenia caused by a rare GPIBB variant
A patient with acquired factor X deficiency and metastatic carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumours?
A patient with mild haemophilia A
Isolated acquired factor VII deficiency: Report of Two Cases and Review of the Literature
Hermansky-Pudlak syndrome
Phenotypical change of the activated protein C resistance ratio after liver transplantation
Acquired factor X deficiency
Diagnosis of a previously unnoticed factor XIII deficiency after ovarian haemorrhage in a 13-year-old girl with extradural haematoma and defective wound healing in her medical history
Lupus Anticoagulant-Hypoprothrombinemia Syndrome
Hermansky Pudlak syndrome
Haemophilia B and treatment, case study
Haemophilia A and treatment, case study
Von Willebrand Jürgens syndrome type I, case study 2016
Acquired Glanzmann’s thrombasthenia
Von Willebrand Jürgens syndrome type I, case study 2019
Trauma-Induced Coagulopathy, case study
Dysfibrinogenemia, case study
Von Willebrand Disease type 2B, case study
A severe haemophilia A patient treated with emicizumab, case study
Acquired haemophilia A
Acquired Hemophilia A, case study
Von Willebrand Disease type 1, case study
Factor V Inhibitor
ECAT Documents :
254
Attempts to align research in thrombosis and hemostasis with the In Vitro Diagnostic Medical Device Regulation (IVDR, EuropeanUnion) requirements
External quality assessment of the manual tilt tube technique for prothrombin time testing: a report from the IFCC-SSC/ISTH Working Group on the Standardization of PT/INR
Short-term biological variation of coagulation and fibrinolytic measurands
Comparison of Thrombophilia Assay Results for the International Society on Thrombosis and Haemostasis Scientific and Standardization Committee Plasma Standard from Different External Quality Assessment Providers—for the External Quality Assurance in Thrombosis and Haemostasis Group
Von Willebrand Factor (VWF)
Vitamin K
Tissue Factor (TF)
Thrombus (plural form is Thrombi)
Thromboplastin
Thrombomodulin
Thrombin Time (TT) Test
Thrombin
Serine Proteases
Reference Interval (range)
PT-Prothrombin Time and Prothrombin Time Ratio
Prothrombin (FII)
Prekallikrein
Platelet
Plasminogen
Phospholipids
Lupus Anticoagulant (LA)
Low Molecular Weight Heparin (LMWH)
ISI-International Sensitivity Index
Intrinsic Pathway of Coagulation
INR-International Normalized Ratio (PT-INR)
Inhibitor
Imprecision
Hypofibrinogenemia
Hirudin
High Molecular Weight Kininogen (HK)
Heparin-Unfractionated
Hemostasis
Hemophilia B
Hemophilia A
Fibrinolysis
Fibrinogen (FI) and Fibrinogen Assay
Fibrin
Factor XIII (FXIII)
Factor XII (FXII)
Factor XI (FXI)
Factor X (FX)
Factor IX Concentrates
Factor IX (FIX)
Factor VIII (FVIII)
Factor VII (FVII)
Factor V Leiden
Factor V (FV)
Extrinsic Pathway of Coagulation
Dysfibrinogenemia
Disseminated Intravascular Coagulation (DIC)
Diagnostic Specificity
Diagnostic Sensitivity
Desmopressin Acetate (DDAVP)
Coumarin
Control Plasma
Contact Activation
Common Pathway of Coagulation
Coagulation Factors
Coagulation Cascade
Coagulation (Clotting)
Clot (Blood Clot)
Bleeding Time
Bias
Bethesda Inhibitor Assay (Titer)
Antithrombin
Antifibrinolytic
Anticoagulant
Aggregometry
Activated Protein C Resistance-APCR
Activated Protein C (APC)
Accuracy
Laboratory issues related to the measurement of efanesoctocog alfa webinar 2025
Activated Partial Thromboplastin Time Test (APTT)
Differential sensitivity of von Willebrand factor activity assays to reduced VWF molecular weight forms: A large international cross-laboratory study
Lack of grading agreement among international hemostasis external quality assessment programs
Detecting molecular forms of antithrombin by LC-MRM-MS: defining the measurands
International normalized ratio (INR) testing in Europe: between-laboratory comparability of test results obtained by Quick and Owren reagents
Complementarity between Bayesian Internal Quality Control results management and External Quality Assessment bivariate z-score analysis: application to a concrete case study
Towards harmonization of external qualityassessment/proficiency testing in hemostasis
D-dimer - An International Assessment of the Quality of Laboratory Testing: Implications for D-dimer Use in the Real World
Pre-analytical practices for routine coagulation tests in European laboratories. A collaborative study from the European Organisation for External Quality Assurance Providers in Laboratory Medicine (EQALM)
Heparin‐induced thrombocytopenia: An international assessment of the quality of laboratory testing
Analytical variation in factor VIII one‐stage and chromogenic assays: Experiences from the ECAT external quality assessment programme
Update on diagnostic testing for platelet function disorders: What is practical and useful?
Determination of sigma score based on biological variation for haemostasis assays: fit-for-purpose for daily practice?
Antiphospholipid antibody solid phase-based assays: problems and proposed solutions for the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome: reply.
Defining a metrologically traceable and sustainable calibration hierarchy of international normalized ratio for monitoring of vitamin K antagonist treatment in accordance with International Organization for Standardization (ISO) 17511:2020 standard: communication from the International Federation of Clinical Chemistry and Laboratory Medicine-SSC/ISTH working group on prothrombin time/international normalized ratio standardization.
Assessment of accuracy of laboratory testing results, relative to peer group consensus values in external quality control, by bivariate z-score analysis: the example of D-Dimer.
International external quality assessment for measurements of direct oral anticoagulants: results and recommendations.
Subcommittee on Plasma Coagulation Inhibitors. Recommendations for clinical laboratory testing for antithrombin deficiency; Communication from the SSC of the ISTH.
Performance of factor IX extended half-life product measurements in external quality control assessment programs
Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data
Laboratory assesment of direct and indirect thrombin inhibitors
Clotting and Fibrinolysis: an integrated test system
Generation assays in coagulation and fibrinolysis: Principles and possibilities
The result of the ECAT HIT surveys
Laboratory testing for heparin induced thrombocytopenia
Laboratory accreditation: the value of quality improvement
The results of the workshop on inhibitor testing
Inhibitor testing: positive or negative? True or False?
A scoring system based on the biological variation
Biological variation of inflammatory and hemostatic markers
Biological variation and analytical quality specifications
Platelet function testing: laboratory tests and quality control
The future of the laboratory diagnosis of thrombofilia
The results of thromboelastography: does it fit with laboratory testing?
Point of care testing for haemostasis. The clinician’s point of view
Point of care testing for haemostasis. The laboratories point of view
Test and equipment evaluation, a practical approach
The results of the ECAT pilot study on FXIII testing
The laboratory diagnosis and classification of FXIII deficiencies
The antiphospholipid syndrome: a laboratory phenomenon?
External quality control: a new decade
Results of the workshop on platelet function testing
Results of the interpretative platelet surveys
Laboratory diagnosis of platelet disorders
The laboratory diagnosis of vWD: current insights
The effect of local ISI calibration on the inter-laboratory variation of the INR
New developments in laboratory tests
Desired tests for monitoring new anticoagulation drugs
An update on new anticoagulation drugs
Factor VIII Inhibitor Testing, the way to better comparison of test results
Lupus Anticoagulant: Remarkable observations in ECAT surveys
Lupus Anticoagulant: Do guidelines work in practice?
Lupus Anticoagulant: Update of the SSC guidelines
Quality planning in the Haemostasis Laboratory
Case studies in Bleeding disorders
Case studies in Thrombophilia
How to use EQA results in the laboratory?
The results of fibrinolytic surveys
The fibrinolytical system, what and how to measure?
Biological variation and quality control
How do laboratories interpret unexpected APTT prolongation?
Towards diagnostic quality control: a pilot study on acquired inhibitors
Algoritm for Laboratory Investigations in Case of a prolonged APTT
Reference Intervals: Practical Approaches
External quality control for CoaguChek XS INR monitors
How to assure the quality of POCT testing
The CLSI & BCSH algorithms for Lupus anticoagulant testing
The SSC algorithm for Lupus testing
Biochemical background of Lupus Anticoagulant
Global haemostasis assays: what will be the future?
Age-dependent cut-off values for D-Dimer testing
Is therapeutic quality influenced by choice of thromboplastin?
First experience of ECAT with Measurement of New Oral Anticoagulation Drugs
Measurement of new oral anticoagulans
Interpretation and management of INR results: a case history based survey in 13 countries
Factor VIII inhibitor testing – a way to comparable test results
The performance of FVIII and FIX measurement in ECAT surveys
Laboratory assays for the measurement of Factor VIII and IX
Gene therapy, the future in hemophilia treatment?
Pre-analytical Variables in the Hemostasis Laboratory
The role of molecular biology in the diagnosis of impaired haemostasis
ECAT survey results for HIT
Heparin Induced Thrombocytopenia; a diagnostic challenge
The pathophysiology of HIT
Quality assurance of the entire diagnostic process
Procedures and barriers for the introduction of a new or improved method: the example of inhibitor testing
Introduction on Inhibitor Testing
ECAT survey results on ADAMTS13 testing
ADAMTS13 and the pathogenesis of Thrombotic Thrombocytopenic Purpura (TTP)
The pathophysiology of Lupus Anticoagulant and the consequences for the laboratory diagnostics
Application of thrombo-elastography in clinical practice and how to control quality
EQA results for POCT INR testing
Establishing reference values - with low number of control samples
Slope and parallelism of APTT dilution curves: new insights
ECAT survey results for low levels of Factor VIII
How to measure low levels of Factor VIII and IX
The new CLSI guideline on Lupus Anticoagulant testing
ECAT survey results on direct oral anticoagulant testing
Monitoring new oral anticoagulants-Practical approach
The future of anticoagulation
Auditing the pre-analytical phase: lessons from 40+ audits across Europe
Thrombosis webinar 2021, Antiphospholipid Antibody, Anticoagulation bridging
Bleeding webinar 2021, von Willebrand
COVID-19 and Haemostasis webinar 2021
"How to interpret the Z-score in survey reports" webinar 2023
Lupus Anticoagulants webinar 2023
How to use EQA results within the laboratory
Rotem, does it have value at the cardiothoracic operation theatre?
Medical device thrombosis
The relevance of pre-operative hemostasis screening
ECAT: Towards sustainable EQA
Introduction on Inhibitor Testing
Haemophilia, new development in patient treatment
The use of Guidelines in Haemostasis Laboratory Testing
Current practice in the pre-analitycal phase
The differential diagnosis between TTP and atypical HUS
Analytical Performance Specifications: the benefit for the laboratory!
The diagnosis of von Willebrand Disease
International Normalized Ratio for monitoring therapy with vitamin K Antagonists
Have international standards in haemostasis improved comparability of laboratory results?
Is standardisation in coagulation feasible?
The role of contact activation in thrombosis and beyond
TFPI: new insights in an old inhibitor
Laboratory Guidelines for Antithrombin, Proteins C and S, and APC-Resistance Testing
Diagnostics in venous thromboembolism: from origin to future prospects
Developmental haemostasis: consequences for clinical practice
Future perspective in quality assurance
Quality Assurance of extended half-life products
Laboratory measurement of extended half-life FVIII
Laboratory measurement of extended half-life FIX
Potency labelling of extended half-life FVIII en FIX products
Treatmentof patients with extended half-life FVIII and FIX products
Results of ECAT EQA programme on DOACS
Interference of DOACS in coagulation tests
Guidance for laboratory testing of DOACS
New developments within ECAT
How to evaluate your Z-score?
Platelet Function Testing
Results of ECAT EQA programme on ROTEM/TEG
Is there a need to measure ROTEM/TEG
The importance of thromboelastography in clinical practice
The use of snake venoms in the coagulation laboratory
A paradigm shift in measuring blood coagulation
Biological variation, quality specifications and Six Sigma
Autovalidation of coagulation test results
Interferences in Lupus testing
Thrombotic APS pathophysiology: consequences for laboratory diagnosis
EFLM/EQALM on the laboratory diagnosis of a prolonged APTT
Crossroads between cancer and coagulation
Inherited FXIII deficiency: laboratory diagnosis
Factor VIII testing: results of ECAT surveys
One-stage clotting assay versus chromogenic testing in the diagnosis of haemophilia patients
Haemophilia treatment and laboratory testing
New developments in haemophilia treatment
Antiphospholipid Antibody Assay results and clinical implications
Follow-up of LA positieve patients
What information does the doctor expect from the laboratory? What kind of services can a laboratory deliver to the physician?
Next-generation antithrombin diagnostics by mass spectrometry
Low von Willebrand Factor and diagnostic treshold
Thrombogenomics
How to interpret the Z-score in survey reports (theory and practical examples)
D-Dimer: quality of laboratory testing and its implications in clinical practice
Hemophilia and gene therapy
When Haemostasis Assays Mislead
Biological Variation in haemostasis
Guidance for FVIII/FIX Inhibitor testing
Sinus thrombosis, past, present and future
The intensive care unit during the COVID-19 pandemic
Method validation for haemostasis assays
What are the implications of the new IVD regulation for the daily laboratory practice?
Determination of lot-to-lot variability of reagents
COVID-19 and the role of the haemostasis laboratory
HIT and VITT: is there a bridge?
Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories
How Do Laboratories Perform von Willebrand Disease Diagnostics and Classification of von Willebrand Disease Patients? Results from External Quality Data and an International Survey
Diagnosis of von Willebrand disease: An assessment of the quality of testing in North American laboratories
Antiphospholipid antibody solid phase–based assays: problems and proposed solutions for the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome
Diagnostic Testing for von Willebrand Disease: Trends and Insights from North American Laboratories over the Last Decade
Anti-PF4 testing for vaccine- induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide
Systematic review and meta-analysis of within-subject and between-subject biological variation data of coagulation and fibrinolytic measurands
International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors
D-dimer diagnostics: can I use any D-dimer assay? Bridging the knowledge-to-action gap
Guidelines :
16
ICSH recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests
Field Study Evaluating Optimal Interpretation Methods for Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies (ICSH)
Laboratory guidance for the evaluation of haemostasis analyser-reagent test systems. Part 1: Instrument-specific issues and commonly used coagulation screening tests. ICSH Recommendations
ICSH Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
ICSH Recommendations for laboratory measurement of ADAMTS13
ICSH Recommendations for Hemostasis Critical Values, Tests, and Reporting
Guidance for New Lot Verification of Coagulation Reagents, Calibrators, and Controls, ICSH recommendations
Laboratory guidance for the verification of haemostasis analyser-reagent test systems. Part 2: Specialist tests and calibrated assays, ICSH recommendations
Recommendations for laboratory measurement of factor VIII and FIX type I inhibitors, ICSH recommendations
Recommendations on fibrinogen assays, thrombin clotting time and related tests in the investigation of bleeding disorders, ICSH recommendations
Recommendations for collection of blood samples for coagulation testing, ICSH recommendations
Recommendations for processing of blood samples for coagulation testing, ICSH recommendations
Update Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, ICSH recommendations
Guidance for INR and D-dimer testing using point of care testing in primary care, ICSH recommendations
Diagnosis and classification of factor XIII deficiencies, SSC recommendation
Thrombin generation measurement in haemophilia, SSC recommendation
Haemostatic Cascade :
9
TF Pathway (Extrinsic) with Common Pathway (PT)
Nucleotide sequences of RNA Codons Encoding for Amino Acids
Intrinsic Pathway APTT
Fibrinolytic Pathway
Coagulation Pathways (All Components)
Amino Acid structure of Natural Hirudin
Activation of TAFI by Thrombin
Activation of Protein C by Thrombin
Activation of Platelets by Thrombin
Quality Issues :
29
How to interpret the Z-score in relation to the homogeneity of the sample used in a survey
Bivariate Z-score Analysis
Harmonizing light transmission aggregometry in the Netherlands by implementation of the SSC-ISTH guideline
An approach for estimating measurement uncertainty in medical laboratories using data from long-term quality control and external quality assessment schemes
A systematic approach for handling unacceptable EQA results
Biological Variation of Hemostasis Variables in Thrombosis and Bleeding: Consequences for Performance Specifications
External quality control for CoaguChek XS INR monitors
The measurement of low Factor XIII activity with the Siemens Berichrom method
How to establish the mean and standard deviation of internal quality control samples to construct control charts.
Quality control in the haemostasis laboratory
Results of the surveys for heparin monitoring
Long-term evaluation of EQA results
Algorithm A, a new statistical approach for the evaluation of survey results
Wet Workshop on Platelet Function Testing
Validation of methods in hemostasis testing: a practical approach
The relevance of accreditation for medical laboratories: An added value for patient care
Quality Assurance of replacement therapy and future perspectives
Internal Quality Control for Coagulation: Repeating the same mistakes as chemistry? Or leaping ahead into the 21st century?
External quality assessment / proficiency testing for platelet function disorders
External Quality Assessment in haemostasis
Does quality matter?
External quality assessment for immunological Heparin-Induced Thrombocytopenia testing
External quality assessment for von Willebrand Factor laboratory analysis
External quality assessment for Factor XIII
External quality assessment for Factor VIII and Factor IX
External quality assessment for Rivaroxaban and Dabigatran
The between-laboratoy variation of Factor VIII inhibitor testing
Bayesian strategy in long-term IQC results management: practical interest and compliance with standards
Interpretation of the Z-score
Surveys and Studies :
14
Pilot Study on Bivalirudin
Pilot Study on Light Transmission Aggregation
Pilot Study on Contact Factor testing
Pre- and Post-analytical Survey 2023
Pre- and Post-analytical Survey 2022
Pre- and Post-analytical Survey 2021
Functional Heparin-Induced Thrombocytopenia Pilot Study
Platelet Light Transmission Aggregation Pilot Study
Fibrin(ogen) Degradation Products Pilot Study
Results of samples spiked with chimeric monoclonal anti-PF4 antibody 1C12 in ECAT external quality assessment surveys for heparin-induced thrombocytopenia (HIT) diagnosis
Emicizumab pilot study, part II
External Quality Control for PFA 100/200
Emicizumab pilot study, part I
Performance of factor IX extended half-life product measurements in external quality control assessment programs
Terminology :
1
Terminology
Questions or suggestions?
Clotpedia Support Form
Submit
Success
